{
    "clinical_study": {
        "@rank": "132654", 
        "arm_group": [
            {
                "arm_group_label": "Olanzapine + Fluoxetine", 
                "arm_group_type": "Experimental", 
                "description": "Olanzapine starting dose is 5 milligram (mg) (1 tablet). May titrate up to 10 mg (2 tablets), or 15 mg (3 tablets) administered once daily by mouth for 8 weeks.\nFluoxetine starting dose is 20 mg. May titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks."
            }, 
            {
                "arm_group_label": "Placebo + Fluoxetine", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo matches the Olanzapine tablet for blinding.\nFluoxetine starting dose is 20 mg, then may titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy and safety of olanzapine and fluoxetine\n      compared to placebo and fluoxetine as treatment for treatment-resistant depression (TRD) in\n      Chinese participants."
        }, 
        "brief_title": "A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Treatment Resistant Depression", 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have single or recurrent unipolar major depressive disorder (MDD) without psychotic\n             features by Diagnostic and Statistical Manual of Mental Disorders, Fourth\n             Edition-Text Revision (DSM-IV-TR) clinical assessment\n\n          -  Have a total score \u226522 on the 17-item Hamilton Depression Rating Scale (HAM-D17) at\n             screening and randomization\n\n          -  Have treatment-resistant depression (TRD), defined as having failed to achieve a\n             satisfactory antidepressant response, in the opinion of the investigator, to separate\n             treatment courses of at least 2 different antidepressants, other than fluoxetine, of\n             adequate dosage and duration (\u22656 weeks) within the current major depressive episode\n\n        Exclusion Criteria:\n\n          -  Have a diagnosis of Parkinson's disease or a related disorder\n\n          -  Have a current or lifetime diagnosis of any of the following conditions, according to\n             DSM-IV-TR criteria: Schizophrenia; Schizophreniform Disorder; Schizoaffective\n             Disorder; Delusional Disorder; Psychotic Disorder Not Otherwise Specified; Bipolar\n             Disorder I or II; Delirium of any type; Dementia of any type; Amnestic Disorder; any\n             Substance-Induced Disorder; or any Psychotic Disorder due to a General Medical\n             Condition\n\n          -  Have a current diagnosis of post-partum depression or MDD with a seasonal pattern as\n             defined in the DSM-IV-TR\n\n          -  Have paranoid, schizoid, schizotypal, antisocial, or borderline personality disorder\n             (Axis II) as a comorbid or primary diagnosis, based on DSM-IV-TR criteria\n\n          -  Have DSM-IV-TR substance dependence/abuse or are not willing to avoid use of the\n             substance (not including dependence on nicotine or caffeine) within 30 days of\n             screening\n\n          -  Are actively suicidal in the judgment of the investigator\n\n          -  Have uncorrected narrow-angle glaucoma\n\n          -  Have had one or more seizures without a clear and resolved etiology\n\n          -  Have leukopenia\n\n          -  Have any acute, serious, or unstable medical conditions\n\n          -  Have an increased serum prolactin concentration at screening\n\n          -  Have a rate-corrected cardiac QT interval, calculated using Bazett's formula (QTc\n             Bazett's [QTcB]), on Electrocardiogram (ECG) >450 milliseconds (male) or >470\n             milliseconds (female) at screening\n\n          -  Have a history of allergic reaction to olanzapine, fluoxetine, or olanzapine in\n             combination with fluoxetine\n\n          -  Have had treatment with olanzapine, fluoxetine, or olanzapine in combination with\n             fluoxetine withdrawn due to clinically significant and/or intolerable adverse effects\n             within 6 months of screening\n\n          -  Have received treatment with remoxipride within 6 months of randomization\n\n          -  Have received treatment with depot antipsychotics within one dosing interval before\n             randomization\n\n          -  Have received electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS)\n             treatment within the current MDD episode, or has a history of failure to respond to\n             adequate treatment courses of ECT or VNS, or is expected to require ECT or VNS at any\n             time during the study\n\n          -  Have received previous treatment with clozapine\n\n          -  Have received treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of\n             screening, or are expected to need MAOI treatment at any time during the study or up\n             until 5 weeks after study discontinuation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "229", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01687478", 
            "org_study_id": "13702", 
            "secondary_id": "F1D-CR-HGNB"
        }, 
        "intervention": [
            {
                "arm_group_label": "Olanzapine + Fluoxetine", 
                "description": "Administered Orally", 
                "intervention_name": "Olanzapine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "LY170053", 
                    "Zyprexa"
                ]
            }, 
            {
                "arm_group_label": [
                    "Olanzapine + Fluoxetine", 
                    "Placebo + Fluoxetine"
                ], 
                "description": "Administered Orally", 
                "intervention_name": "Fluoxetine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "LY110140", 
                    "Prozac"
                ]
            }, 
            {
                "arm_group_label": "Placebo + Fluoxetine", 
                "description": "Administered Orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluoxetine", 
                "Olanzapine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 17, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Baoding", 
                        "country": "China", 
                        "zip": "071000"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100088"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "zip": "410011"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Guang Zhou", 
                        "country": "China", 
                        "zip": "560370"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "zip": "310009"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Kunming", 
                        "country": "China", 
                        "zip": "650032"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "zip": "210029"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200030"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Wu Han", 
                        "country": "China", 
                        "zip": "430022"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Xi'An", 
                        "country": "China", 
                        "zip": "710032"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Xinxiang", 
                        "country": "China", 
                        "zip": "453002"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Study to Assess the Short-Term Efficacy and Safety of Olanzapine and Fluoxetine Compared to Placebo and Fluoxetine for Nonpsychotic Treatment-Resistant Depression", 
        "overall_contact": {
            "last_name": "There maybe multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559)", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean Change from Baseline to 8 Week Endpoint in Montgomery-\u00c4sberg Depression Rating Scale (MADRS)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, up to 8 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01687478"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean Change from Baseline to 8 Week Endpoint in Clinical Global Impressions-Severity of Depression (CGI-S) Scale", 
                "safety_issue": "No", 
                "time_frame": "Baseline, up to 8 Weeks"
            }, 
            {
                "measure": "Mean Change from Baseline to 8 Week Endpoint in the Simpson-Angus Scale (SAS)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, up to 8 Weeks"
            }, 
            {
                "measure": "Mean Change from Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, up to 8 Weeks"
            }, 
            {
                "measure": "Mean Change from Baseline to 8 Week Endpoint in the Sheehan Disability Scale (SDS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, up to 8 Weeks"
            }, 
            {
                "measure": "Percentage of Participants who Achieve a Response Based on a \u226550% Reduction from Baseline in MADRS Total Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 8 Weeks"
            }, 
            {
                "measure": "Percentage of Participants who Achieve Remission Based on MADRS Total Score \u226410 at 8 Weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to 8 Weeks"
            }, 
            {
                "measure": "Mean Change from Baseline to 8 Week Endpoint in the Barnes Akathisia Scale (BAS)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, up to 8 Weeks"
            }, 
            {
                "measure": "Mean Change from Baseline to 8 Week Endpoint in the Abnormal Involuntary Movement Scale (AIMS)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, up to 8 Weeks"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}